Rossari Biotech Ltd's Q1FY26 Quarterly Results

Result Summary

• Rossari Biotech Ltd reported a 15.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1FY26). On a year-on-year (YoY) basis, it witnessed a growth of 11.1%.
• Its expenses for the quarter were up by 16.7% QoQ and 12.5% YoY.
• The net profit decreased 1.6% QoQ and decreased 3.7% YoY.
• The earnings per share (EPS) of Rossari Biotech Ltd stood at 6.1 during Q1FY26.

Financial Statments for Q1FY26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Rossari Biotech Ltd is a company that specializes in providing chemical solutions for various industries. The primary focus of the company is on the production and marketing of specialty chemicals, which serve sectors such as home and personal care, textiles, and performance chemicals. Rossari Biotech has established itself as a key player within the chemical industry, offering innovative solutions tailored to the needs of its clients. Recent major developments in the company are not available, but historically, Rossari has been known to focus on expanding its product line and enhancing its manufacturing capabilities to meet growing demand.

Revenue

In Q1FY26, Rossari Biotech Ltd reported total income of ₹544.92 crores. This represents an increase of 15.2% on a quarter-over-quarter basis from Q4FY25, where the total income was ₹473.10 crores. When compared to Q1FY25, where the total income stood at ₹490.60 crores, there is a year-over-year growth of 11.1%. The upward trend in total income across both quarterly and yearly comparisons indicates a positive trajectory in revenue generation for the company during this period.

Profitability

The company's profit before tax (PBT) for Q1FY26 was ₹45.58 crores. This marks a slight quarter-over-quarter growth of 0.4% from Q4FY25, which recorded a PBT of ₹45.38 crores. However, on a year-over-year basis, there is a decrease of 2.6%, as the PBT in Q1FY25 was ₹46.78 crores. After accounting for taxes, Rossari Biotech's profit after tax (PAT) for Q1FY26 was ₹33.60 crores, reflecting a decline of 1.6% from the previous quarter's PAT of ₹34.13 crores and a decrease of 3.7% compared to ₹34.90 crores in Q1FY25. The earnings per share (EPS) also experienced a decline, with the Q1FY26 EPS at ₹6.10, down 1.6% from Q4FY25 and 3.2% from Q1FY25.

Operating Metrics

Total expenses for Rossari Biotech Ltd in Q1FY26 were ₹499.34 crores, representing an increase of 16.7% quarter-over-quarter from ₹427.71 crores in Q4FY25. Year-over-year, there was a 12.5% increase from ₹443.81 crores in Q1FY25. The tax expense for Q1FY26 was ₹12.50 crores, which is a 9.3% increase from the previous quarter's tax expense of ₹11.44 crores and a 3.4% increase from ₹12.09 crores recorded in Q1FY25. The financial metrics indicate changes in both income and expenses, reflecting the company's operational adjustments during this period.